T2 Biosystems, Inc. (TTOO)
NASDAQ: TTOO · IEX Real-Time Price · USD
5.07
-0.10 (-1.93%)
At close: Jul 19, 2024, 4:00 PM
5.11
+0.04 (0.79%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
T2 Biosystems Revenue
T2 Biosystems had revenue of $7.18M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $2.06M. In the year 2023, T2 Biosystems had annual revenue of $7.19M.
Revenue (ttm)
$7.18M
Revenue Growth
-58.15%
P/S Ratio
10.86
Revenue / Employee
$63,504
Employees
113
Market Cap
77.91M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.19M | -15.11M | -67.75% |
Dec 31, 2022 | 22.31M | -5.75M | -20.50% |
Dec 31, 2021 | 28.06M | 9.93M | 54.76% |
Dec 31, 2020 | 18.13M | 9.80M | 117.52% |
Dec 31, 2019 | 8.34M | -2.17M | -20.62% |
Dec 31, 2018 | 10.50M | 5.83M | 125.03% |
Dec 31, 2017 | 4.67M | 586.00K | 14.36% |
Dec 31, 2016 | 4.08M | 1.27M | 45.04% |
Dec 31, 2015 | 2.81M | 2.69M | 2,263.87% |
Dec 31, 2014 | 119.00K | -147.00K | -55.26% |
Dec 31, 2013 | 266.00K | 247.00K | 1,300.00% |
Dec 31, 2012 | 19.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetMed Express | 281.06M |
Eagle Pharmaceuticals | 257.55M |
Spero Therapeutics | 110.98M |
MDxHealth | 75.33M |
SHL Telemedicine | 57.08M |
Marinus Pharmaceuticals | 28.29M |
Forian | 20.49M |
Affimed | 4.26M |
TTOO News
- 2 months ago - T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements - GlobeNewsWire
- 2 months ago - T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - T2 Biosystems Announces CRG's Conversion from Preferred Stock to Common Stock - GlobeNewsWire
- 2 months ago - T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease - GlobeNewsWire
- 2 months ago - T2 Biosystems Announces Commercial Expansion Through Middle East Distributor - GlobeNewsWire
- 2 months ago - T2 Biosystems Announces First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity - GlobeNewsWire